The United States has recorded its highest annual total of confirmed measles infections in 35 years, with 2,318 cases reported nationwide in 2026. This surge highlights ongoing challenges in maintaining robust public health defenses, particularly against vaccine-preventable diseases. The majority of these cases, 69%, occurred among individuals aged 19 or younger, with children under five accounting for one-fifth of all infections. A striking 93% of confirmed measles cases were among unvaccinated people, according to national health data.
Kindergarten measles, mumps, and rubella (MMR) vaccination coverage currently stands at 92.5%. This figure falls below the 95% threshold widely recognized by public health experts as necessary to achieve effective herd immunity, which protects vulnerable populations who cannot be vaccinated, such as infants and those with compromised immune systems. The gap in vaccination rates has contributed to the susceptibility of communities to outbreaks, making the current rise in measles a significant concern for public health officials.
Internationally, the Democratic Republic of the Congo has reported a substantial Ebola outbreak. Following a comprehensive data review, nearly 3,000 confirmed cases have been identified, resulting in more than 1,269 deaths. The scale of this outbreak underscores the persistent threat of infectious diseases in regions with limited healthcare infrastructure and the global interconnectedness of public health challenges. Efforts to contain and treat the disease continue, with international organizations providing support to local health authorities.
Domestically, federal agencies are managing several widespread foodborne illness investigations. The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have expanded their investigation into a cyclospora outbreak. This outbreak has been linked to shredded iceberg lettuce imported from central Mexico. To date, 1,947 cases of illness and 98 hospitalizations have been reported across nine states, though no deaths have occurred. The affected lettuce was promptly recalled from the market, and the implicated processing facility in Mexico was temporarily closed as part of the ongoing investigation to prevent further contamination.
In a separate food safety incident, Midwest Poultry Services initiated a recall of nearly 1.6 million dozen eggs. This widespread recall was issued due to a potential risk of Salmonella contamination, a bacterium that can cause severe gastrointestinal illness. Consumers were advised to check their egg cartons for specific codes and discard any affected products.
Beyond infectious disease and food safety, the pharmaceutical industry and regulatory landscape have seen notable developments. A federal judge recently dismissed a shareholder lawsuit filed against Abbott Laboratories. The suit concerned the company’s 2022 powdered infant-formula recall, which originated from its Sturgis, Michigan, plant. Judge Steven Seeger ruled that the shareholders had not presented sufficient evidence to demonstrate that Abbott Laboratories intended to deceive them regarding the issues that led to the recall. This decision marks a significant development in the legal aftermath of a recall that impacted infant formula supply chains across the country.
In pharmaceutical policy, Merck has entered into agreements covering an experimental HIV pill across 129 countries. These agreements aim to broaden access to potential new treatments for HIV, particularly in low- and middle-income income nations where the burden of the disease is highest. The move reflects ongoing efforts by pharmaceutical companies and global health initiatives to address health disparities.
The FDA has also been active on several fronts. The agency decided to exclude the peptide emideltide from pharmacy-compounding lists, a move that affects how certain medications can be prepared and dispensed by compounding pharmacies. Conversely, the FDA recommended Semax for inclusion on these lists, indicating its potential utility in compounded formulations. These decisions reflect the FDA’s ongoing oversight of drug safety and efficacy in various pharmaceutical preparations.
Furthermore, a Virginia federal judge issued an order requiring the FDA to reassess special licensing requirements for prescribing mifepristone. This ruling could have implications for access to the medication, which is used for medication abortion, by potentially altering the regulatory framework under which it is prescribed and dispensed. The FDA is expected to review its current requirements in light of the judicial order.
Why it matters in Greenville
The convergence of national health challenges, from rising measles cases to widespread foodborne illness outbreaks and shifts in pharmaceutical regulation, directly impacts public health infrastructure and healthcare providers in Greenville. Local institutions like Prisma Health and Bon Secours St. Francis, two of the region’s major employers and healthcare anchors, must remain vigilant in monitoring these trends. A national measles surge, for instance, necessitates heightened awareness and vaccination efforts within Greenville County to protect vulnerable populations and prevent local outbreaks. Similarly, food recalls and regulatory changes in pharmaceuticals can affect local supply chains, patient care protocols, and public health advisories issued by Greenville County Government. These national developments underscore the continuous need for robust public health surveillance and preparedness within the Greenville area to safeguard community well-being.
